Published: Mon, October 01, 2018
Medicine | By Earnest Bishop

Nobel Prize in Medicine Awarded for Immune System Cancer Research

Nobel Prize in Medicine Awarded for Immune System Cancer Research

Cancerous tumors are notoriously skilled at dodging our immune systems. It will ultimately make a way for the cancer immunotherapy which acts as a major retaliatory force in the battle against cancer. This practice contrasts with radiation therapy and standard chemotherapy, which directly attack cancerous tumors.

Allison, an American immunologist, conducted a study on a protein that functions as a brake on the immune system.

Charles Swanton, chief clinician at the charity Cancer Research UK, said the scientists' work had revolutionised cancer and immunotherapy.

Allison was "elated" by the award, says his longtime friend and colleague Lewis Lanier, a professor and chair of the Department of Microbiology and Immunology at the University of California, San Francisco, who says he spoke with Allison just after the announcement. He was born in Kyoto.

Around the same time, Honjo discovered a protein on immune cells, the ligand PD-1, and eventually realised that it also worked a brake, but it acted differently. Their procedures relied on antibodies-proteins made to bind and interfere with other proteins.

Thanks to Allison's doggedness, anti-CTLA-4 therapy is now an accepted therapy for cancer and it opened the floodgates for a slew of new immunotherapies, Krummel said. It, too, operates as a T-cell brake, but via a different molecular mechanism than CTLA-4. Rapidly producing a broad diversity of T-cells increases the likelihood of making a T-cell that would recognize and kill an evasive tumor.

Wozniacki, Kerber both upset at Wuhan Open
"I feel like the difference is who's going to take their opportunities and their chances, who's going to make or miss the shots". She will now face Wang Qiang of China , who ousted Australia's Daria Gavrilova 7-5, 6-2 to the delight of the home crowd.

Meanwhile, Allison left UC Berkeley in 2004 for Memorial Sloan Kettering research center in NY to be closer to the drug companies shepherding his therapy through clinical trials, and to explore in more detail how checkpoint blockade works. In 1992, his lab found another off-switch for T-cells embedded in their membranes: a protein called PD-1.

By the 1970s Allison had developed a strong fascination for T-cells, soldiers of the immune system that help defend the body against foreign invaders.

This scenario can also occur when a person has had a cancer for a long time.

For decades researchers had been trying to figure out effective ways to use the body's own immune system against cancer.

Allison joined the UC Berkeley faculty as a professor of molecular and cell biology and director of the Cancer Research Laboratory in 1985.

USA drugmakers Merck & Co and Bristol-Myers Squibb now lead the field after winning drug approvals in 2014, but Roche, AstraZeneca, Pfizer and Sanofi are also fielding rivals. Worldwide, cancer is the second leading cause of mortality-with 70 percent of these deaths occurring in low- and middle-income countries.

Like this: